Corcept Therapeutics Incorporated (0I3Q.L)
USD 55.58
(-0.47%)
USD 55.58
(-0.47%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 368.61 Million USD | 29.87% |
| 2022 | 283.83 Million USD | 20.16% |
| 2021 | 236.22 Million USD | 7.33% |
| 2020 | 220.09 Million USD | 16.22% |
| 2019 | 189.37 Million USD | 20.98% |
| 2018 | 156.53 Million USD | 52.28% |
| 2017 | 102.79 Million USD | 48.79% |
| 2016 | 69.08 Million USD | 31.92% |
| 2015 | 52.36 Million USD | -1.73% |
| 2014 | 53.28 Million USD | 3.05% |
| 2013 | 51.71 Million USD | 30.95% |
| 2012 | 39.48 Million USD | 22.13% |
| 2011 | 32.33 Million USD | 17.84% |
| 2010 | 27.43 Million USD | 35.3% |
| 2009 | 20.27 Million USD | 1.91% |
| 2008 | 19.89 Million USD | 56.34% |
| 2007 | 12.72 Million USD | -50.82% |
| 2006 | 25.87 Million USD | 22.3% |
| 2005 | 21.15 Million USD | 31.87% |
| 2004 | 16.04 Million USD | 60.54% |
| 2003 | 9.99 Million USD | -46.82% |
| 2002 | 18.79 Million USD | 134.76% |
| 2001 | 8 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 114.77 Million USD | 12.68% |
| 2024 Q2 | 125.68 Million USD | 9.5% |
| 2024 Q3 | 133.08 Million USD | 5.89% |
| 2023 Q3 | 90.77 Million USD | 4.88% |
| 2023 Q1 | 89.41 Million USD | 13.07% |
| 2023 FY | 368.61 Million USD | 29.87% |
| 2023 Q2 | 86.55 Million USD | -3.2% |
| 2023 Q4 | 101.85 Million USD | 12.21% |
| 2022 Q3 | 68.45 Million USD | -3.09% |
| 2022 Q1 | 65.66 Million USD | 8.0% |
| 2022 Q4 | 79.07 Million USD | 15.52% |
| 2022 FY | 283.83 Million USD | 20.16% |
| 2022 Q2 | 70.63 Million USD | 7.57% |
| 2021 Q4 | 60.8 Million USD | 3.72% |
| 2021 Q3 | 58.62 Million USD | 0.62% |
| 2021 Q2 | 58.26 Million USD | -0.46% |
| 2021 FY | 236.22 Million USD | 7.33% |
| 2021 Q1 | 58.53 Million USD | 8.45% |
| 2020 FY | 220.09 Million USD | 16.22% |
| 2020 Q3 | 60.39 Million USD | 15.98% |
| 2020 Q2 | 52.06 Million USD | -2.96% |
| 2020 Q1 | 53.65 Million USD | 4.31% |
| 2020 Q4 | 53.97 Million USD | -10.63% |
| 2019 FY | 189.37 Million USD | 20.98% |
| 2019 Q2 | 46.24 Million USD | 3.62% |
| 2019 Q1 | 44.63 Million USD | 10.6% |
| 2019 Q4 | 51.44 Million USD | 9.34% |
| 2019 Q3 | 47.05 Million USD | 1.74% |
| 2018 Q4 | 40.35 Million USD | 0.46% |
| 2018 FY | 156.53 Million USD | 52.28% |
| 2018 Q2 | 40.52 Million USD | 14.18% |
| 2018 Q3 | 40.16 Million USD | -0.88% |
| 2018 Q1 | 35.49 Million USD | 16.64% |
| 2017 Q4 | 30.42 Million USD | 8.04% |
| 2017 Q2 | 21.98 Million USD | -1.01% |
| 2017 Q3 | 28.16 Million USD | 28.08% |
| 2017 FY | 102.79 Million USD | 48.79% |
| 2017 Q1 | 22.21 Million USD | 21.76% |
| 2016 Q1 | 15.06 Million USD | 16.32% |
| 2016 Q2 | 17.79 Million USD | 18.08% |
| 2016 Q3 | 17.98 Million USD | 1.1% |
| 2016 Q4 | 18.24 Million USD | 1.44% |
| 2016 FY | 69.08 Million USD | 31.92% |
| 2015 Q3 | 12.9 Million USD | 1.73% |
| 2015 Q4 | 12.95 Million USD | 0.38% |
| 2015 Q2 | 12.68 Million USD | -8.29% |
| 2015 FY | 52.36 Million USD | -1.73% |
| 2015 Q1 | 13.83 Million USD | 16.88% |
| 2014 Q2 | 12.21 Million USD | -28.51% |
| 2014 Q3 | 12.15 Million USD | -0.55% |
| 2014 FY | 53.28 Million USD | 3.05% |
| 2014 Q4 | 11.83 Million USD | -2.61% |
| 2014 Q1 | 17.09 Million USD | 21.34% |
| 2013 Q2 | 12.65 Million USD | 0.09% |
| 2013 FY | 51.71 Million USD | 30.95% |
| 2013 Q4 | 14.08 Million USD | 14.19% |
| 2013 Q3 | 12.33 Million USD | -2.51% |
| 2013 Q1 | 12.64 Million USD | 11.48% |
| 2012 Q3 | 8.7 Million USD | 3.36% |
| 2012 Q2 | 8.41 Million USD | -23.66% |
| 2012 FY | 39.48 Million USD | 22.13% |
| 2012 Q1 | 11.02 Million USD | 11.09% |
| 2012 Q4 | 11.33 Million USD | 30.29% |
| 2011 Q2 | 8.86 Million USD | 24.95% |
| 2011 FY | 32.33 Million USD | 17.84% |
| 2011 Q1 | 7.09 Million USD | -9.28% |
| 2011 Q4 | 9.92 Million USD | 54.23% |
| 2011 Q3 | 6.43 Million USD | -27.42% |
| 2010 Q4 | 7.82 Million USD | 10.12% |
| 2010 FY | 27.43 Million USD | 35.3% |
| 2010 Q3 | 7.1 Million USD | 10.24% |
| 2010 Q2 | 6.44 Million USD | 6.28% |
| 2010 Q1 | 6.06 Million USD | 17.45% |
| 2009 Q4 | 5.16 Million USD | 10.56% |
| 2009 FY | 20.27 Million USD | 1.91% |
| 2009 Q3 | 4.67 Million USD | -4.46% |
| 2009 Q2 | 4.88 Million USD | -12.05% |
| 2009 Q1 | 5.55 Million USD | -9.77% |
| 2008 Q3 | 4.96 Million USD | 6.0% |
| 2008 Q2 | 4.68 Million USD | 14.79% |
| 2008 Q1 | 4.08 Million USD | -7.6% |
| 2008 FY | 19.89 Million USD | 56.34% |
| 2008 Q4 | 6.16 Million USD | 23.99% |
| 2007 Q3 | 3.61 Million USD | 85.25% |
| 2007 Q4 | 4.41 Million USD | 22.14% |
| 2007 FY | 12.72 Million USD | -50.82% |
| 2007 Q1 | 2.73 Million USD | -32.68% |
| 2007 Q2 | 1.95 Million USD | -28.62% |
| 2006 Q3 | 6.54 Million USD | -19.78% |
| 2006 Q2 | 8.16 Million USD | 14.99% |
| 2006 Q4 | 4.06 Million USD | -37.94% |
| 2006 Q1 | 7.1 Million USD | 28.97% |
| 2006 FY | 25.87 Million USD | 22.3% |
| 2005 Q3 | 5.48 Million USD | 24.97% |
| 2005 Q1 | 5.78 Million USD | 4.79% |
| 2005 FY | 21.15 Million USD | 31.87% |
| 2005 Q4 | 5.5 Million USD | 0.44% |
| 2005 Q2 | 4.38 Million USD | -24.21% |
| 2004 Q4 | 5.52 Million USD | 29.7% |
| 2004 FY | 16.04 Million USD | 60.54% |
| 2004 Q2 | 3.69 Million USD | 43.75% |
| 2004 Q3 | 4.25 Million USD | 15.25% |
| 2004 Q1 | 2.57 Million USD | 25.76% |
| 2003 Q2 | 2.92 Million USD | 1.99% |
| 2003 Q4 | 2.04 Million USD | -5.47% |
| 2003 Q3 | 2.16 Million USD | -26.03% |
| 2003 FY | 9.99 Million USD | -46.82% |
| 2003 Q1 | 2.86 Million USD | 0.0% |
| 2002 FY | 18.79 Million USD | 134.76% |
| 2001 FY | 8 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Editas Medicine, Inc. | 247.3 Million USD | -49.052% |
| Dynavax Technologies Corporation | 219.14 Million USD | -68.205% |
| Supernus Pharmaceuticals, Inc. | 529.01 Million USD | 30.321% |
| Perrigo Company plc | 1.52 Billion USD | 75.884% |
| Illumina, Inc. | 3.81 Billion USD | 90.333% |
| Thermo Fisher Scientific Inc. | 10.25 Billion USD | 96.405% |
| Iovance Biotherapeutics, Inc. | 450.99 Million USD | 18.267% |
| Walgreens Boots Alliance, Inc. | 40.6 Billion USD | 99.092% |
| IQVIA Holdings Inc. | 2.05 Billion USD | 82.045% |
| Heron Therapeutics, Inc. | 120.65 Million USD | -205.504% |
| Regeneron Pharmaceuticals, Inc. | 2.81 Billion USD | 86.907% |
| Unity Biotechnology, Inc. | 44.66 Million USD | -725.245% |
| Waters Corporation | 943.51 Million USD | 60.932% |
| Biogen Inc. | 5.2 Billion USD | 92.918% |
| Sangamo Therapeutics, Inc. | 228.68 Million USD | -61.191% |
| Evolus, Inc. | 189.75 Million USD | -94.253% |
| Adicet Bio, Inc. | 152.03 Million USD | -142.447% |
| Cara Therapeutics, Inc. | 142.46 Million USD | -158.742% |
| bluebird bio, Inc. | 240.23 Million USD | -53.44% |
| Esperion Therapeutics, Inc. | 271.89 Million USD | -35.57% |
| FibroGen, Inc. | 398.11 Million USD | 7.41% |
| Agilent Technologies, Inc. | 2.11 Billion USD | 82.572% |
| Corbus Pharmaceuticals Holdings, Inc. | 13.9 Million USD | -2550.047% |
| Homology Medicines, Inc. | 9.87 Million USD | -3632.78% |
| Geron Corporation | 70.44 Million USD | -423.292% |
| Alnylam Pharmaceuticals, Inc. | 1.8 Billion USD | 79.522% |
| Amicus Therapeutics, Inc. | 427.65 Million USD | 13.805% |
| Myriad Genetics, Inc. | 600.1 Million USD | 38.575% |
| Viking Therapeutics, Inc. | 100.82 Million USD | -265.589% |
| Intellia Therapeutics, Inc. | 551.56 Million USD | 33.17% |
| Zoetis Inc. | 2.76 Billion USD | 86.669% |
| Abeona Therapeutics Inc. | 48.5 Million USD | -659.993% |
| Mettler-Toledo International Inc. | 1.08 Billion USD | 66.163% |
| BioMarin Pharmaceutical Inc. | 1.74 Billion USD | 78.892% |
| Vertex Pharmaceuticals Incorporated | 4.77 Billion USD | 92.28% |
| Kala Pharmaceuticals, Inc. | 39.15 Million USD | -841.466% |
| Ionis Pharmaceuticals, Inc. | 779.58 Million USD | 52.717% |
| Atara Biotherapeutics, Inc. | 275.69 Million USD | -33.704% |
| Verastem, Inc. | 92.08 Million USD | -300.3% |
| Nektar Therapeutics | 190.9 Million USD | -93.089% |
| Axsome Therapeutics, Inc. | 476.36 Million USD | 22.619% |
| Aclaris Therapeutics, Inc. | 12.14 Million USD | -2936.093% |
| Sarepta Therapeutics, Inc. | 1.36 Billion USD | 72.912% |
| OPKO Health, Inc. | 574.68 Million USD | 35.859% |
| Exelixis, Inc. | 1.58 Billion USD | 76.77% |
| Neurocrine Biosciences, Inc. | 1.59 Billion USD | 76.911% |
| Anavex Life Sciences Corp. | 55.75 Million USD | -561.116% |
| uniQure N.V. | 285.08 Million USD | -29.299% |
| Imunon, Inc. | 21.03 Million USD | -1652.755% |
| Blueprint Medicines Corporation | 722.86 Million USD | 49.007% |
| Insmed Incorporated | 949.26 Million USD | 61.169% |
| Halozyme Therapeutics, Inc. | 299.31 Million USD | -23.151% |
| Agios Pharmaceuticals, Inc. | 408.8 Million USD | 9.832% |
| TG Therapeutics, Inc. | 198.47 Million USD | -85.722% |
| Incyte Corporation | 1.19 Billion USD | 69.037% |
| Emergent BioSolutions Inc. | 1.04 Billion USD | 64.692% |